Erlotinib-associated acute pneumonitis: Report of two cases

作者: Bobbak Vahid , Ali Esmaili

DOI: 10.1155/2007/832605

关键词:

摘要: Two cases of erlotinib-associated acute pneumonitis are described. The first patient was started on erlotinib treatment for metastatic non-small cell lung cancer. second treated with adenocarcinoma unknown origin. Both patients developed dyspnea and hypoxemia five to six days after initiation treatment. In both cases, computed tomography scan the chest showed extensive bilateral ground-glass infiltrates consistent pneumonitis. patients, resulted in respiratory failure requiring intubation mechanical ventilation. Diffuse alveolar hemorrhage excluded by bronchoscopy cases. Bronchoalveolar lavage cultures were negative. Erlotinib stopped corticosteroids. improved gradually finally discharged a rehabilitation centre, but unfortunately died Klebsiella sepsis. Naranjo causality scale suggested probable association between Literature is sparse. clinical presentation radiographic findings

参考文章(13)
Cora N Sternberg, Andrea Mancuso, New treatments for metastatic kidney cancer. Canadian Journal of Urology. pp. 66- ,(2005)
Kelly A. Tammaro, Patricia D. Baldwin, Ante S. Lundberg, Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). Journal of Oncology Pharmacy Practice. ,vol. 11, pp. 127- 130 ,(2005) , 10.1191/1078155205JP158CR
P Camus, S Kudoh, M Ebina, Interstitial lung disease associated with drug therapy British Journal of Cancer. ,vol. 91, ,(2004) , 10.1038/SJ.BJC.6602063
N L Müller, D A White, H Jiang, A Gemma, Diagnosis and management of drug-associated interstitial lung disease. British Journal of Cancer. ,vol. 91, ,(2004) , 10.1038/SJ.BJC.6602064
Toshimi Takano, Yuichiro Ohe, Masahiko Kusumoto, Ukihide Tateishi, Seiichiro Yamamoto, Hiroshi Nokihara, Noboru Yamamoto, Ikuo Sekine, Hideo Kunitoh, Tomohide Tamura, Tetsuro Kodama, Nagahiro Saijo, Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib Lung Cancer. ,vol. 45, pp. 93- 104 ,(2004) , 10.1016/J.LUNGCAN.2004.01.010
A.N. GORDON, N. FINKLER, R.P. EDWARDS, A.A. GARCIA, M. CROZIER, D.H. IRWIN, E. BARRETT, Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. International Journal of Gynecological Cancer. ,vol. 15, pp. 785- 792 ,(2005) , 10.1111/J.1525-1438.2005.00137.X
T Higenbottam, K Kuwano, B Nemery, Y Fujita, Understanding the mechanisms of drug-associated interstitial lung disease. British Journal of Cancer. ,vol. 91, ,(2004) , 10.1038/SJ.BJC.6602065
Denis Soulieres, Neil N. Senzer, Everett E. Vokes, Manuel Hidalgo, Sanjiv S. Agarwala, Lillian L. Siu, Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Journal of Clinical Oncology. ,vol. 22, pp. 77- 85 ,(2004) , 10.1200/JCO.2004.06.075
Daphne A. Haas-Kogan, Michael D. Prados, Tarik Tihan, David A. Eberhard, Nannette Jelluma, Nils D. Arvold, Rachel Baumber, Kathleen R. Lamborn, Ami Kapadia, Mary Malec, Mitchel S. Berger, David Stokoe, Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib Journal of the National Cancer Institute. ,vol. 97, pp. 880- 887 ,(2005) , 10.1093/JNCI/DJI161
Martin H. Cohen, John R. Johnson, Yeh‐Fong Chen, Rajeshwari Sridhara, Richard Pazdur, FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. ,vol. 10, pp. 461- 466 ,(2005) , 10.1634/THEONCOLOGIST.10-7-461